Continue reading this on our app for a better experience

Open in App
Floating Button
Home Capital Results

Vicplas International posts 2.1 times earnings growth for FY21, declares DPS of 0.45 cents

Atiqah Mokhtar
Atiqah Mokhtar • 2 min read
Vicplas International posts 2.1 times earnings growth for FY21, declares DPS of 0.45 cents
Vicplas reported earnings of $10.4 mil for FY21, 112.5% higher y-o-y.
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Vicplas International has posted earnings of $10.4 million for FY2021 ended July, up 112.5% from $4.9 million the previous year.

This translates to earnings per share of 2 cents on a fully diluted basis, up from 0.98 cents the previous year.

See also: Vicplas International reports 2.2 times earnings growth for 1HFY21

Revenue for the period increased by 28.2% to $113.9 million in FY2021 from $88.8 million in FY2020, driven by higher revenue from both medical devices and pipes and pipe fittings segments.

The higher revenue was driven by both its medical devices as well as its pipes and pipe fittings segment. The medical devices segment saw revenue increase 30.6% to $80.2 million in FY2021, due to increased orders from its customers, while revenue from the pipes and pipe fittings segment increased 22.9% to $33.8 million, due to the gradual recovery in the construction industry from the disruptions caused by the Covid-19 pandemic.

Other income increased by 32.4% in FY2021 to $6.9 million due to more tools built for customers in the medical devices segment and foreign exchange gain, despite a $0.9 million reduction in Covid-19 related government subsidies in FY2021 as compared to FY2020.

The group recorded a profit before tax of $12.3 million and a profit after tax of 10.4 million for FY2021, up 71.6% y-o-y.

Vicplas is recommending a final dividend of 0.45 cents per ordinary share for FY2021, 20% higher than the dividend of 0.375 cents per share for FY2020.

For more stories about where the money flows, click here for our Capital section

In view of opportunities to keep growing the Group’s medical devices segment, Vicplas sstates more capital has been retained in the business to support such growth in the long term interest of shareholders. In addition, the group is mindful of the uncertainties in the macro environment as well as the Group’s working capital, cashflow and capital expenditure requirements.

“In FY2021, Vicplas achieved its best results ever with the medical devices segment’s positive growth trajectory and the pipes and pipe fittings segment recovering in tandem with the construction industry. With a challenging operating environment due to the ongoing Covid-19 pandemic and uncertainties in the wider macro environment, the Group remains cautiously optimistic for the year ahead,” says Cheng Liang, Vicplas’ CEO.

As at 9.55am, shares in Vicplas are down 3 cents or 11.1% lower at 24 cents.

Highlights

Re test Testing QA Spotlight
1000th issue

Re test Testing QA Spotlight

Get the latest news updates in your mailbox
Never miss out on important financial news and get daily updates today
×
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.